assay
≥97% (HPLC)
Quality Level
form
solid
potency
34 nM IC50
color
off-white
solubility
DMSO: 25 mg/mL, methanol: soluble
General description
A negative control for MAP kinase inhibition studies.
A negative control for SB202190 and SB203580 in p38 MAP kinase inhibition studies.
Biochem/physiol Actions
p38β
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
存储类别
11 - Combustible Solids
法规信息
新产品
此项目有
R Nath et al.
Cellular & molecular biology letters, 6(2), 173-184 (2001-09-07)
The mitogen-activated protein kinase (MAPK) cascades are thought to be important mediators in the transduction of extracellular signals into cellular responses. The p38 kinase, a member of the MAPK superfamily, is activated by a wide variety of extracellular stimuli and
R Yu et al.
The Journal of biological chemistry, 275(4), 2322-2327 (2000-01-25)
Phase II drug-metabolizing enzymes, such as glutathione S-transferase and quinone reductase, play an important role in the detoxification of chemical carcinogens. The induction of these detoxifying enzymes by a variety of agents occurs at the transcriptional level and is regulated
Sarah Lockhead et al.
Cell reports, 32(2), 107901-107901 (2020-07-16)
Protein synthesis inhibitors (e.g., cycloheximide) block mitotic entry, suggesting that cell cycle progression requires protein synthesis until right before mitosis. However, cycloheximide is also known to activate p38 mitogen-activated protein kinase (MAPK), which can delay mitotic entry through a G2/M